• Underlying EBIT growth of 1.7% with 20 bps margin expansion
• Underlying NPAT growth of 4.3% driven by improved earnings
• Revenue down 0.7% due to lower market growth and Medicare funding cuts
• ACL's MBS outlays reduced by 1.0% vs market growth
• $47.1m in capital returns to shareholders

Australian Clinical Labs Limited (ASX: ACL) reported its financial results for the 12 months to 30 June 2026 (FY26). The company delivered underlying EBIT growth of 1.7% and underlying NPAT growth of 4.3%. Total revenue declined by 0.7% due to lower market growth, Medicare funding cuts to B12 and urine tests, and ongoing ACC optimisation. ACL's Medicare Benefits Schedule (MBS) outlays reduced by 1.0% compared to market growth. The company returned $47.1 million to shareholders through dividends and share buybacks. For FY27, ACL expects revenue between $745 million and $765 million and underlying EBIT between $67 million and $73 million, implying an underlying EBIT margin of 9.0% to 9.5%.

FY27 revenue guidance: $745m to $765m; Underlying EBIT: $67m to $73m

ACL is focused on strategic initiatives to offset labor costs and improve revenue quality. The company expects modest market growth and plans to maintain strong capital discipline.